...
首页> 外文期刊>Advanced drug delivery reviews >Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology.
【24h】

Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology.

机译:用于口服和胃肠外给药的纳米化:使用湿介质研磨技术配制水溶性差的化合物的观点。

获取原文
获取原文并翻译 | 示例
           

摘要

A significant percentage of active pharmaceutical ingredients identified through discovery screening programs is poorly soluble in water. These molecules are often difficult to formulate using conventional approaches and are associated with innumerable formulation-related performance issues, e.g. poor bioavailability, lack of dose proportionality, slow onset of action and other attributes leading to poor patient compliance. In addition, for parenteral products, these molecules are generally administered with co-solvents and thus have many undesirable side effects. Wet media milling is one of the leading particle size reduction approaches that have been successfully used to formulate these problematic compounds. The approach is a water-based media milling process where micron-sized drug particles are shear-fractured into nanometer-sized particles. Nanoparticle dispersions are stable and typically have a mean diameter of less than 200 nm with 90% of the particles being less than 400 nm. The formulation consists only of water, drug and one or more GRAS excipients. Drug concentrations approaching 300-400mg/g can be targeted with the use of minimal amounts stabilizer. Typically, on average, the drug to stabilizer ratio on a weight basis ranges from 2:1 to 20:1. These liquid nanodispersions exhibit acceptable shelf-life and can be post-processed into various types of solid dosage forms. Nanoparticulate-based drug products have been shown to improve bioavailability and enhance drug exposure for oral and parenteral dosage forms. Suitable formulations for the most commonly used routes of administration can be identified with milligram quantities of drug substance providing the discovery scientist an alternate avenue for screening and identifying superior leads. In the last few years, formulating poorly water soluble compounds as nanosuspensions has evolved from a conception to a realization. The versatility and applicability of this drug delivery platform are just beginning to be realized.
机译:通过发现筛选程序确定的很大一部分活性药物成分难溶于水。这些分子通常难以使​​用常规方法来配制,并且与无数与制剂有关的性能问题有关,例如生物利用度差,剂量比例不足,起效缓慢以及其他导致患者依从性差的属性。另外,对于肠胃外产品,这些分子通常与助溶剂一起施用,因此具有许多不良副作用。湿法研磨是减少颗粒尺寸的主要方法之一,已成功地用于配制这些有问题的化合物。该方法是一种水基介质研磨工艺,其中将微米级的药物颗粒剪切破碎为纳米级的颗粒。纳米颗粒分散体是稳定的,并且通常具有小于200nm的平均直径,其中90%的颗粒小于400nm。该制剂仅由水,药物和一种或多种GRAS赋形剂组成。使用最小量的稳定剂可以达到接近300-400mg / g的药物浓度。通常,以重量计,药物与稳定剂的平均比例平均为2:1至20:1。这些液体纳米分散体表现出可接受的保存期限,并且可以被后加工成各种类型的固体剂型。已经显示出基于纳米颗粒的药物产品改善了生物利用度并增加了口服和肠胃外剂型的药物暴露。可以用毫克数量的原料药确定最常用的给药途径的合适制剂,为发现科学家提供了筛选和鉴定优质铅的替代途径。在过去的几年中,将水溶性差的化合物制成纳米悬浮液已从概念发展为实现。该药物递送平台的多功能性和适用性才刚刚开始被认识到。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号